Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer

被引:34
作者
Gregorc, Vanesa
Spreafico, Anna
Floriani, Irene
Colombo, Barbara
Ludovini, Vienna
Pistola, Lorenza
Bellezza, Guido
Vigano, Maria Grazia
Villa, Eugenio
Corti, Angelo
机构
[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy
[2] Monteluce Policlin, Div Med Oncol, Perugia, Italy
[3] Ist Ric Farmacol Mario Negri, Lab Clin Trials, Milan, Italy
[4] Monteluce Policlin, Dept Pathol, Perugia, Italy
[5] IIT Network Res Unit Mol Neurosci, Milan, Italy
关键词
chromogranin A; tumor necrosis factor; nonsmall cell lung cancer; survival; performance status;
D O I
10.1002/cncr.22856
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. increased levels of chromogranin A (CgA), a protein secreted by many neuroendocrine cells, have been detected in sera of patients with neuroendocrine tumors or renal, hepatic, or heart failure. In patients with heart failure, serum CgA correlates with tumor necrosis factor-alpha (TNF) and soluble TNF receptors (sTNF-Rs), with important prognostic implications. The prognostic value of CgA and sTNF-Rs was investigated in advanced nonsmall cell lung cancer (NSCLC), a histologically heterogeneous group of tumors that may undergo neuroendocrine differentiation. METHODS. CgA and sTNF-Rs were analyzed in the sera of 88 patients with NSCLC before chemotherapy by enzyme-linked immunoadsorbent assay (ELISA) and in tumors by immunohistochemistry. RESULTS. Thirteen percent of patients had CgA values greater than the highest value observed in normal subjects (distribution range, 9-724 ng/mL and 28-196 ng/mL, respectively). Immunohistochemical studies showed no correlation between CgA expression in tumors and serum levels. Conversely, circulating CgA was associated with worse Eastern Cooperative Oncology Group (ECOG) performance status (PS) (P =.0005), more advanced stage (P =.042), and survival, with CgA being an independent prognostic factor of poor outcome (hazards ratio [HR] 1.31 for 100 ng/mL increase; 95% confidence interval [95% CI] 1.08-1.60 [P =.0071]). sTNF-R1 and sTNF-R2 were also associated with ECOG PS (P =.0001 and P =.02, respectively). sTNF-Rs was weakly correlated with circulating CgA (r = 0.39 for TNF-RI and r = 0.40 for TNF-R2), suggesting a regulatory link between sTNF-Rs and CgA secretion. CONCLUSIONS. increased serum levels of CgA in NSCLC are independent from protein expression in tumors and more likely related to neuroendocrine response associated with worsening of patient condition. In addition to ECOG PS and stage, CgA is an independent indicator of poor prognosis.
引用
收藏
页码:845 / 853
页数:9
相关论文
共 40 条
  • [1] Aderka Dan, 1996, Cytokine and Growth Factor Reviews, V7, P231, DOI 10.1016/S1359-6101(96)00026-3
  • [2] Tumor necrosis factor-α in the pathogenesis and treatment of cancer
    Anderson, GM
    Nakada, MT
    DeWitte, M
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (04) : 314 - 320
  • [3] Angelsen A, 1997, PROSTATE, V30, P1
  • [4] [Anonymous], BIOL THERAPY CANC
  • [5] Neuroendocrine differentiation in carcinoma of the breast - Tyramide signal amplification discloses chromogranin A-positive tumour cells in more breast tumours than previously realized
    Bofin, AM
    Qvigstad, G
    Waldum, C
    Waldum, HL
    [J]. APMIS, 2002, 110 (09) : 658 - 664
  • [6] Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis
    Borch, K
    Stridsberg, M
    Burman, P
    Rehfeld, JF
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (03) : 198 - 202
  • [7] Bovver M, 2004, Cancer Ther, V2, P131
  • [8] NEUROENDOCRINE DIFFERENTIATION AS A PROGNOSTIC FACTOR IN NONSMALL CELL LUNG-CANCER
    CARLES, J
    ROSELL, R
    ARIZA, A
    PELLICER, I
    SANCHEZ, JJ
    FERNANDEZVASALO, G
    ABAD, A
    BARNADAS, A
    [J]. LUNG CANCER, 1993, 10 (3-4) : 209 - 219
  • [9] Chromogranin A in heart failure - A novel neurohumoral factor and a predictor for mortality
    Ceconi, C
    Ferrari, R
    Bachetti, T
    Opasich, C
    Volterrani, M
    Colombo, B
    Parrinello, G
    Corti, A
    [J]. EUROPEAN HEART JOURNAL, 2002, 23 (12) : 967 - 974
  • [10] Colombo B, 2002, CANCER RES, V62, P941